Search result from the Trials Tracker
Study details
The Cystic Fibrosis working group recent recommendations commended the use of physical exercise as part of a multidisciplinary therapeutic strategy, as it has been proven to lower mortality risks in patients. One nonpharmacological intervention which has shown some promising results in recent years is inspiratory muscle training (IMT), which may improve patients’ respiratory muscle and exercise function. Inspiratory muscle training, which involves breathing through a device that provides resistance when you breathe, aims to improve the strength of the lung muscles by making them work harder and therefore making them stronger. Starting IMT in children at the early years of...
- Trials Tracker ID
- TT001676
- Age range
- 8 years and older
- Length of participation
- 8 - 16 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
Study details
CF START is a national UK trial that will determine the safest and most effective antibiotic strategy for infants diagnosed with cystic fibrosis (CF). 480 CF infants will be randomly allocated either flucloxacillin prophylaxis (the current UK standard of care) or antibiotics given in a more targeted manner. The primary outcome will be the age at first growth of Pseudomonas aeruginosa from a respiratory culture (an important safety measure for families). All outcomes will be recorded on a national CF Registry, including a number of secondary outcomes assessing effectiveness and safety. Finally at 40-48 months, a measure of respiratory function...
- Trials Tracker ID
- TT001671
- Age range
- 0 to 4 years
- Length of participation
- 48 months
- Trial status
- Recruitment complete
- Therapeutic approach
- Anti-Infective
Search result from the Trials Tracker
Study details
This study will look at whether two drugs (called lumacaftor and ivacaftor) can help treat cystic fibrosis when taken together over a long period of time. It will also look at whether they are safe over this period. You can only take part in this study if you took part in a study called VX14-809-109, and if you meet certain criteria. These criteria will be checked by the study doctor and nurse at a screening visit. If you meet these criteria you will be treated with lumacaftor and ivacaftor together for approximately 96 weeks. A follow up visit will be...
- Trials Tracker ID
- TT001661
- Age range
- 6 years and older
- Length of participation
- 96 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This trial has been archived
Study details
This study aims to find out if CF patients benefit from ‘virtual care’ while they are receiving intravenous (IV) antibiotics in the community. ‘Virtual care’ is a term that we are using to describe the provision of regular videoconferencing with the CF team as well as equipment to allow patients to monitor their own lung function and oxygen saturations.
- Trials Tracker ID
- TT001656
- Age range
- 18 years and older
- Length of participation
- 2 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
This trial has been archived
Study details
Cystic fibrosis affects around 10,000 people in the UK and an estimated > 100,000 worldwide. It is a multisystem condition, with lung disease being the most significant, leading to early infection, inflammation and scarring. Currently, despite huge improvements in clinical care, the median age of death in the UK is just over 30 years. Babies are now diagnosed on newborn screening and are usually asymptomatic, but lung disease begins early. Disease progression is variable and influenced by a number of factors, one of the most important being the frequency of pulmonary exacerbations (PEx), poorly understood periods of increasing symptoms and...
- Trials Tracker ID
- TT001646
- Age range
- Between 0 and 17 years
- Length of participation
- 6 Months
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
Study details
Acute changes in respiratory signs and symptoms termed Pulmonary Exacerbations require treatment with intravenous antibiotics and hospital admission. These episodes cause substantial disruption to people's lives and impact on lung function, quality of life and lifespan. Current treatment regimes require improvement but further study is needed to identify who might benefit from a different approach. This observational study aims to assess if multi-dimensional measurements taken during treatment correspond with later treatment response. This may allow us to personalise treatment more effectively in the future and to better understand how individuals respond to treatment. As yet there is no model for...
- Trials Tracker ID
- TT001641
- Age range
- 18 years and older
- Trial status
- Recruitment complete
- Therapeutic approach
- Other
Search result from the Trials Tracker
This trial has been archived
Study details
The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation
Study results summary
Ivacaftor was generally safe and well tolerated in children aged 4 to 24 months. Treatment for up to 24 weeks was associated with reductions in sweat chloride and improvements in the function of the pancreas. All adverse events reported were considered mild or moderate and likely not related to Ivacaftor treatment.
- Trials Tracker ID
- TT001611
- Age range
- Between 0 and 24 months
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
The study is being done to learn more about the effectiveness of Kalydeco in CF patients with the following specific gene mutaions: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D. The study also looks to explore the effect of Kalydeco on your quality of life. This is an observational study. This means that your cystic fibrosis treatment and medical care will not change because you are participating in this study and the sponsor will not pay for Kalydeco. Your doctor will continue to make all decisions regarding your proper treatment and care. No part of this study is experimental.
- Trials Tracker ID
- TT001606
- Age range
- 6 years and older
- Length of participation
- 48 months
- Trial status
- Recruitment complete
- Therapeutic approach
- Other
